Overexpression of cyclooxygenase 2 in hamartomatous polyps of Peutz-Jeghers syndrome

American Journal of Gastroenterology

Volumn 98, Issue 3, 2003, Pages 671-678

  McGarrity, Thomas J ^a   Peiffer, Laurie P ^b   Amos, Christopher I ^b   Frazier, Marsha L ^b   Ward, Margaret G ^b   Howett, Mary K ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ORNITHINE DECARBOXYLASE; RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; GASTROINTESTINAL TRACT; HAMARTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE POLYP; LAMINA PROPRIA; MEASUREMENT; MUSCLE CELL; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA;

EID: 0037343907     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07328.x     Document Type: Article

References (51)

1. Peutz J. Very remarkable case of familial polyposis of mucous membrane of intestinal tract and vasopharynx accompanied by peculiar pigmentation of skin and mucous membranes. Ned Maandskr Geneeshd 1921;10:139-46.
2. Jeghers H, McKusick VA, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, eyes and digits. N Engl J Med 1949;241:993-1005, 1031-6.
3. McGarrity TJ, Kulin HE, Zaino RJ. Peutz-Jeghers syndrome. Am J Gastroenterol 2000;95:596-604.
4. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-53.
5. Laughlin EH. Benign and malignant neoplasms in a family with Peutz-Jeghers syndrome: A study of three generations. South Med J 1991;84:1205-9.
6. Foley TR, McGarrity TJ, Abt AB. Peutz-Jeghers syndrome: A clinicopathologic survey of the "Harrisburg family" with a 49-year follow up. Gastroenterology 1988;95:1535-40.
7. Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38-43.
8. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-7.
9. Kargman JL, O'Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-9.
10. Lenore TL, Hubbard WC, Litterst CL, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res 1988;48:3140-7.
11. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107: 1183-8.
12. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9.
13. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
14. Debinski HS, Trojan J, Nugent KP, et al. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 1995; 345:855-6.
15. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-9.
16. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
17. Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996;111:1134-40.
18. Maekawa M, Sugano K, Sano H, et al. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Japn J Clin Oncol 1998;25:421-6.
19. Sheehan KM, Sheahen K, O'Donaghue DP, et al. The relationship between cyclooxygenase 2 expression and colorectal cancer. JAMA 1999;282:1254-7.
20. Steinbach G, Lynch PM, Phillips RK, et al. The effects of Celecoxib, a cyclooxygenase-2 inhibitor in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
21. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 1988;48:759-74.
22. Seiler N, Atanassov CL, Raul F. Polyamine metabolism as a target for cancer chemoprevention. Int J Oncol 1998;13:993-1006.
23. Luk GD, Baylin SB. Ornithine decarboxylase as a biological marker in familial colonic polyposis. N Engl J Med 1984;311: 80-3.
24. Giardiello FM, Hamilton SR, Hylind LM, et al. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 1997;57:199-201.
25. Boyle JO, Meyskens FL Jr, Garewal HS, Gerner EW. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 1992;1:131-5.
26. Meyskens FL Jr, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemopreventive agent. Clin Cancer Res 1999;5:945-51.
27. To KF, Chan FK, Cheng AS, et al. Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer. Aliment Pharmacol Ther 2001;15:25-34.
28. Endoh M, Kashem A, Yamauchi F, et al. Expression of thromboxane synthase in kidney tissues from patients with IgA nephropathy. Clin Nephrol 1997;47:168-75.
29. Perzin KH, Bridge MF. Adenomatous and carcinomatous changes in hamartomatous polyps of the small intestine (Peutz-Jeghers syndrome). Cancer 1982;49:971-83.
30. Konishi F, Wyse NE, Muto T, et al. Peutz-Jeghers polyposis associated with carcinoma of the digestive organs. Dis Colon Rectum 1987;30:790-9.
31. Bujanda L, Beguiristain A, Villar VM, et al. Gastric adenocarcinoma in hamartomatous polyp in Peutz-Jeghers syndrome. Gastroenterol Hepatol 1996;19:452-5.
32. Reid JD. Intestinal carcinoma in the Peutz-Jeghers syndrome. JAMA 1974;229:833-4.
33. Matuchansky C, Babin P, Coutrot S, et al. Peutz-Jeghers syndrome with metastasizing carcinoma arising from a jejunal hamartoma. Gastroenterology 1979;77:1311-5.
34. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996;110:1259-62.
35. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993;90:7804-8.
36. Pena A, Reddy CD, Wu S, et al. Regulation of human ornithine decarboxylase expression by the c-Myc. Max protein complex. J Biochem 1993;268:27277-85.
37. Hixson LJ, Emerson SS, Shassetz LR, Gerner EW. Sources of variability in estimating ornithine decarboxylase activity and polyamine content in human colorectal mucosa. Cancer Epidemiol Biomarkers Prev 1994;3:317-23.
38. Nakagawa H, Koyama K, Miyoshi Y, et al. Nine novel germline mutations of STK11 in ten families with Peutz-Jeghers syndrome. Hum Genet 1998;103:168-72.
39. Boardman LA, Couch FJ, Burgart LJ, et al. Genetic heterogeneity in Peutz-Jeghers syndrome. Hum Mutat 2000;16:23-30.
40. Amos CI, Frazier ML, McGarrity TJ. Peutz-Jeghers syndrome (February 2001). In: GeneClinics Clinical Genetic Information Resource (database online). Copyright, University of Washington, Seattle. Available at: http://www.geneclinics.org.
41. Grober SB, Entius MM, Petersen GM, et al. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res 1998;58:5267-70.
42. Karuman P, Gozani O, Odze RD, et al. The Peutz-Jeghers gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell 2001;7:1307-19.
43. McGarrity TJ, Peiffer LP, Billingsley ML. Overexpression of epidermal growth factor receptor in Peutz-Jeghers syndrome. Dig Dis Sci 1999;44:1136-41.
44. Robertson KW, Reeves JR, Smith G, et al. Quantitative estimation of epidermal growth factor receptor and C-erb B-2 in human breast cancer. Cancer Res 1996;56:3823-30.
45. Pegram M, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
46. Barnard JA, Beauchamp RD, Russell WE, et al. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995;108:564-80.
47. Coffey RJ, McCutchen CM, Graves-Deal R, Polk WH. Transforming growth factors and related peptides in gastrointestinal neoplasia. J Cell Biochem 1992;16G:111-8.
48. Coffey RJ, Hawkey CJ, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997;94:657-62.
49. Gupta RA, DuBois RN. Combinations for cancer prevention. Nat Med 2000;6:974-5.
50. Vadlamudi R, Mandal M, Adam L, et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999; 18:305-14.
51. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6: 1024-8.